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Background: The mechanism by which anemia results in lowered hepcidin levels is not clear.
Results: Bonemorphogenetic protein (BMP)-binding endothelial cell precursor-derived regulator (BMPER), a known BMP antago-
nist, was found to be up-regulated in anemic Trfhpx/hpx mice and to suppress hepcidin transcription both in vivo and in vitro.
Conclusion: BMPER is involved in suppressing hepcidin levels in Trfhpx/hpx mice.
Significance: BMPER is a novel regulator of hepcidin and iron metabolism.
The BMP/SMAD4 pathway has major effects on liver hepci-
din levels. Bone morphogenetic protein-binding endothelial
cell precursor-derived regulator (Bmper), a known regulator of
BMP signaling, was found to be overexpressed at themRNAand
protein levels in liver of genetically hypotransferrinemic mice
(Trfhpx/hpx). Soluble BMPER peptide inhibited BMP2- and
BMP6-dependent hepcidin promoter activity in both HepG2
and HuH7 cells. These effects correlated with reduced cellular
levels of pSMAD1/5/8. Addition of BMPER peptide to primary
human hepatocytes abolished the BMP2-dependent increase in
hepcidin mRNA, whereas injection of Bmper peptide into mice
resulted in reduced liver hepcidin and increased serum iron lev-
els. Thus Bmpermay play an important role in suppressing hep-
cidin production in hypotransferrinemic mice.
Hepcidin is secreted into the circulation by hepatocytes and
plays a central role in the regulation of iron metabolism (1–3).
Hepatic hepcidin levels are regulated by iron stores (1), hypoxia,
erythropoietic rate, and inflammatory status (4, 5). Hepcidin
works by blocking the entry of iron into the circulation from the
gut and the macrophages by binding to the iron transporter
Ferroportin resulting in its ubiquitylation and degradation (6,
7). Low levels of circulating hepcidin are associated with many
forms of genetic iron overload (8, 9). Various signaling path-
ways have been shown to regulate hepatic hepcidin levels with
bone morphogenetic proteins, Bmps2 (especially Bmp2, Bmp4,
Bmp6, and Bmp9), which signal via SMADs, emerging as key
players (10–13). Bmp signaling is extraordinarily complex with
a number of extracellular Bmp ligands, including crossvein-
less-2 (CV-2), Twisted gastrulation (Twsg1), chordin, noggin,
and hemojuvelin (hjv), which can act as either pro- and anti-
Bmp effectors depending on the context and concentration
(14). TWSG1was recently shown to be elevated in patientswith
thalassemia and to negatively regulate hepcidin by inhibiting
the effects of BMP2 and 4 (15).
Crossveinless-2 (Cv-2) was identified in Drosophila where it
was implicated in Bmp signaling and shown to be essential for
the formation of small blood vessels or “crossveins” in the wing
(16). The orthologous mouse protein named bone morphoge-
netic protein (Bmp)-binding endothelial cell precursor-derived
regulator (Bmper) is highly expressed in developing endothelial
cells and binds to Bmp2, -4, and -6 inhibiting BMP signaling
(17). Further evidence in zebrafish Bmper mutants supports a
role in Bmp signaling during vascular development (18). Bmper
has been shown to have both pro- and anti-Bmp activity (16, 17,
19, 20). The protein exists in two forms, a full-length mem-
brane-associated form and a soluble form consisting of a het-
erodimer of C- and N-terminal cleavage fragments connected
via disulfide bonding (19). The cleavage is autocatalytic via a
conserved acid-sensitive cleavage site (FGDPH) and is sug-
gested to account for the ability of the protein to act as a pro- or
anti-Bmp in vivo (19). The N terminus of Bmper contains five
cysteine-rich von Willebrand type C-like domains (named
CR1–5) responsible for ligand binding that are conserved in
other BMP-binding proteins such as chordin. Bmper binds
Bmps with high affinity similar to that of Bmp type I and type II
receptors themselves (19). The C-terminal of Bmper contains a
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furin-like, a von Willebrand type D, and a trypsin inhibitor
domain (16).
Hypotransferrinemic mice (Trfhpx/hpx) have defective trans-
ferrin gene expression leading to low levels of plasma transfer-
rin (1% of wild type) and, despite massive iron loading, have
very low levels of hepcidin in hepatocytes (21). The precise
mechanism of hepcidin suppression in Trfhpx/hpx mice, as in
other conditions of enhanced erythropoiesis, anemia, and
hypoxia, remains unclear and may involve a number of signal-
ing pathways. We sought to identify potential hepcidin regula-
tors produced locally in liver of Trfhpx/hpx mice.We identified a
known Bmp regulator Bmper as being highly up-regulated in
liver of Trfhpx/hpx mice. In this report we show that Bmper can
suppress hepcidin promoter activity and reduce hepcidin levels
in liver cells both in vitro and in vivo via effects on the BMP
pathway.
EXPERIMENTAL PROCEDURES
Animals—HPX mice (Trfhpx/hpx) were bred and maintained
as described previously (22). Homozygous Trfhpx/hpxmice were
identified at birth. Normal littermates (mixture of Trf/ and
Trfhpx/) were used as controls. To study the effect of Bmper
injections,male 6-week-old CD-1mice (4mice per group) were
injected intraperitoneally with 50 g of mouse Bmper peptide
dissolved in PBS (R&D Systems) or PBS alone. After 18 h mice
were sacrificed and liver RNA extracted. Hepcidin mRNA was
determined by real-time PCR (described below). Serum iron
was determined using a commercial kit (Quanti chrom, Bioas-
says). All animal experiments were performed under a UK
Home Office License.
Microarrays—Liver RNAwas extracted usingTRIzol reagent
(Invitrogen) from two male HPXmice and two maleWTmice.
Labeled cDNA was synthesized according to the manufactur-
er’s instructions (Affymetrix, Santa Clara, CA) and hybridized
to Mouse Genome 430 2.0 Arrays (Affymetrix). Gene expres-
sion analysis was performed using Genespring software (Agi-
lent Technologies, Santa Clara, CA).
Western Blotting and Immunocytochemistry—Whole cell
lysates were extracted from mouse liver tissue samples by
homogenization in 500 l of RIPA buffer (10 mM Tris, 150 mM
Nacl, 1 mM EDTA, 1% Nonidet P-40, 0.1% SDS) and protease
inhibitor mixture (1:200 dilution, Sigma-Aldrich). The homo-
genates were centrifuged at 3000 rpm at 4 °C for 5 min. The
resulting supernatant was quantified using a BSA assay (Bio-
Rad), resolved by SDS-PAGE, and transferred onto a PVDF
membrane. Membranes were incubated sequentially with pri-
mary and secondary antibodies. Primary antibodies, Crossvein-
less-2 (R&DSystems), pSMAD1/5/8, and SMAD1 (Cell Signal-
ing Technology), or actin (Sigma-Aldrich) were used for
Western blots and/or immunocytochemistry. Following incu-
bation with the appropriate secondary antibodies, blots were
visualized by chemiluminescence (Pierce, Thermo Scientific).
For immunocytochemistry, liver samples from mice were fro-
zen in freezingmedium (Bright Instruments) using liquid nitro-
gen. Sections (5-m thickness) were cut using a cryostat
microtome (Bright Instruments) and placed on polylysine-
coated slides (VWR International, Leuven, Belgium). Sections
were fixed in 100% acetone for 10 min at 4 °C before being
incubated for 20 min in blocking buffer (1% BSA in PBS) fol-
lowed by incubation in primary antibody for crossveinless-2
(1:100) for 1 h. Thereafter, sections were washed in PBS and
incubated with FITC-conjugated anti-goat secondary (Dako),
1:50 for 20 min, followed by washing in PBS and addition of
mountingmedium containing propidium iodide (Vector Labo-
ratories). Images were captured using an LS-2 confocal micro-
scope (Leica).
Real-time PCR—One microgram of total RNA was reverse-
transcribed, and cDNA was synthesized using a Transcriptor
High Fidelity cDNA kit (Roche Diagnostics). All primers were
designed using Universal Probe Library system (Roche Diag-
nostics) software, and qPCRwas performed using anABI Prism
3700 PCR machine (ABI). See supplemental materials for all
primer sequences. Results were normalized to the housekeep-
ing gene RPL-19 and expressed as -fold change using the
method of Livak and Schmittgen (23).
Cell Culture and Hepcidin Promoter Assays—Hepatic cells
HuH7 and HepG2 were obtained from the ATCC and cultured
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS,
Sigma), penicillin-streptomycin (Sigma), and glutamine
(Sigma). Cell cultures were maintained at 37 °C under 95%
air/5%CO2. Cells (2.5 105 cells/ml) were seeded onto 24-well
plates for transfections. Recombinant human peptides for
BMP2 and BMP6, BMPER, and TWSG1 were obtained from
R&D Systems. Approximately 2.7 kb of the human hepcidin
promoter relative to the transcriptional start site containing the
three known BMP response elements (BMP-RE1–3) (24) was
subcloned into the pGL3-basic luciferase reporter vector (Pro-
mega) utilizingMluI andHindIII restriction sites. In addition, a
mutant hepcidin promoter was generated by substituting two
nucleotides in the BMP RE2 from GGCGCC to GGAACC
(position 2250 to 2246 relative to the transcriptional start
site) using a QuikChange site-directed mutagenesis kit (Strat-
agene). All constructs were sequenced. The pGL3-hepcidin
reporter constructs were co-transfected into cells with a TK-
Renilla control reporter at a 3:1 ratio using Fugene-6 (Roche)
according to themanufacturer’s instructions. After 6 h, the cells
were treatedwith humanBMP-2 (25 ng/ml, 16–18 h) or human
BMP-6 (25 ng/ml, 16–18 h), in the presence or absence of
human BMPER (1–2500 ng/ml, 16–18 h) or human TWSG1
(1–1000 ng/ml, 16–18 h). Luminescence was detected using
the Dual-Luciferase Reporter Assay system (Promega) and
measured by using a luminometer (Promega). Relative lucifer-
ase activity was calculated and expressed as the ratio of the
signal of firefly luciferase to TK-Renilla.
Primary Hepatocytes—Human hepatocytes were isolated
fromdonor liver segments/lobes. All tissueswere consented for
research in accordance with the Research Ethics Committee of
King’s College Hospital. Cell isolation was carried out using a
modified two-step collagenase perfusion technique, and hepa-
tocytes were purified by low speed centrifugation at 50 g for 5
min at 4 °C (25). Cells were cryopreserved in University ofWis-
consin solution containing 10% DMSO using a controlled-rate
freezer and stored at 140 °C before rapid thawing for use.
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Statistical Analysis—Data are presented as means  S.D.
Data analysis was performed using SPSS (IBM), and statistical
differences were determined where appropriate using either
ANOVA followed by Tukey’s post hoc test or two-tailed Stu-
dent’s t test.
RESULTS
BMPER Levels in Trfhpx/hpx Mice—As previously shown by
others (21, 26) hepcidin levels are lowered in Trfhpx/hpx relative
to controlmice (Fig. 1A). In contrast Bmper protein andmRNA
levels were both markedly increased in liver of Trfhpx/hpx mice
comparedwith controlmice (Fig. 1,A–C). In liver sections from
control mice BMPER protein expression appeared to be
restricted to cells lining blood vessels, whereas in Trfhpx/hpx
mice, BMPER expression was observed in other cell types,
including hepatocytes (Fig. 1C).
Effect of BMPER Peptide on Hepcidin Transcription—We
investigated the effect of recombinant soluble human BMPER
peptide on hepcidin transcription using hepcidin promoter
reporter (luciferase) assays in two liver cell lines, HepG2 and
HuH7. BMPER treatment strongly inhibited BMP2-dependent
hepcidin promoter activity at a molar ratio of 1:15 (BMP2:
BMPER) in both cell lines (Fig. 2, A and B). The hepcidin pro-
moter contains three known BMP response elements (BMP-
RE1–3, Fig. 2D). BMP-RE1 and -2 are essential for BMP-depen-
dent regulation of hepcidin transcription (24). In agreement
with previous studies of Casanovas and colleagues (24), we
found that mutation of the BMP-RE2 greatly reduced the
responsiveness of the hepcidin promoter to BMP2 (Fig. 2,A and
B). In agreementwith the previous results we found the residual
promoter activity of the mutated construct showed a similar
pattern to the WT construct in the presence of BMP2 and
BMPER albeit at a lower level (Fig. 2, A and B). To confirm that
the effects of BMPER were via SMAD signaling, pSMAD1/5/8
levels weremeasured byWestern blotting (Fig. 2,A andB, lower
panels). As expected pSMAD 1/5/8 levels were increased by
BMP2 treatment, and this induction was suppressed by the
presence BMPER in both cell lines (Fig. 2, A and B, lower pan-
els). The ratio of pSMAD1/5/8:SMAD1 was significantly
reduced in HepG2 cells treated with BMP2 and BMPER com-
pared with BMP2 treatment alone (Fig. 2C).
Effect of BMPER Peptide on HAMP Levels in Human Primary
Hepatocytes—To confirm the effects of BMPERon endogenous
Hamp levels we used isolated primary human hepatocytes
treated with and without BMP2 and measured Hamp mRNA
levels by qPCR. Exposure of primary hepatocytes to BMP2
alone produced a 3-fold induction inHampmRNA levels, how-
ever in the presence of BMPER this effect was abolished (Fig. 3).
Thus, consistent with the effect of BMPER on the hepcidin
promoter assays, BMPER can robustly modulate endogenous
Hamp mRNA levels in primary hepatocytes.
BMPER Inhibits BMP6-mediated Induction of Hepcidin
Transcription—Because BMP6 is thought to be the iron stores
regulator and has been shown to be important in modulating
iron metabolism (13), we tested the effect of BMPER against
BMP6 using luciferase hepcidin promoter assays. Addition of
increasing amounts of BMPER resulted in a significant inhibi-
tion of BMP6-induced hepcidin promoter activity (Fig. 4A),
although the effect was lessmarked than for BMP2 (35% reduc-
tion of Bmp6-induced activity compared with a 90% reduction
of BMP2-mediated activity).
Effect of BMPER and TWSG1, Alone or in Combination, on
Hepcidin Promoter Activity—TWSG1 has also been shown to
inhibit BMP-mediated effects in hepcidin promoter studies,
whereas other studies have suggested Bmper and Twsg1 inter-
act to form a ternary complex together with that of Bmp (27).
When given alone, BMPER exhibited a dose response inhibi-
tion against BMP2 (25 ng/ml)-mediated activity resulting in an
83% reduction in activity at 1000 ng/ml (equivalent to 1:6molar
ratio BMP2:BMPER) (Fig. 4B). TWSG1 also exhibited a dose
response but was less potent than BMPER, inhibiting BMP2
effects by only 46% at 1000 ng/ml (equivalent to a 1:23 molar
ratio BMP2:TWSG1). When both TWSG1 and BMPER were
added jointly BMP2-induced hepcidin transcriptional activity
was decreased to similar levels to that observed with BMPER
alone indicating there was no additive effect.
Effect of Bmper Injection in NormalMice—To investigate the
effect of Bmper in vivo CD1 mice were injected with a single
dose of 50 g of mouse Bmper peptide. After 18 h mice were
sacrificed, and serum iron and liver hepcidin mRNA levels
FIGURE 1. BMPER expression in Trfhpx/hpx mice. A, qPCR shows relative
Bmper and hepcidin mRNA levels (the results were normalized to the house-
keeping gene RPL-19) in 10- and 11-week-old male Trfhpx/hpx mice (n  3).
Trfhpx/ were used as control (C) mice (n  3). The inset gel picture shows a
semiquantitative RT-PCR assay for Bmper and hepcidin in the same samples. B,
Western blots showing BMPER expression in the same mice as in A. C, BMPER
staining (green) in liver sections from male, 7-week-old Trfhpx/hpx compared
with age- and sex-matched control (Trfhpx/?), counterstain is propidium
iodide (*, p  0.003; †, p  0.03, compared with control mice, Student’s t test).
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were measured. Compared with control saline-injected mice,
mice injected with BMPER peptide showed a significant
increase in serum iron together with a significant decrease in
liver hepcidin mRNA levels (Fig. 5).
We also measured the mRNA levels of other known BMP
antagonists (Hjv, Noggin, Chordin, and Twsg1) as well as the
hepcidin inhibitor Gdf15 by qPCR in liver of Trfhpx/hpx mice
and controls. We found no significant changes in any of the
BMP antagonists listed, however levels of Gdf15 were signifi-
cantly raised in liver of Trfhpx/hpx mice (Fig. 6A). Because some
BMP antagonists such as Hjv are highly expressed in other tis-
sues such as skeletal muscle we also measured levels of Hjv,
Noggin, and Chordin in skeletal muscle of Trfhpx/hpx mice and
controls (Fig. 6B). No significant changes were found.
Multiple sequence alignment of BMPER and HJV protein
sequences from several species (human, mouse, and zebrafish)
reveal that both proteins share a vonWillebrand typeDdomain
and a fully conserved acid-sensitive autocatalytic domain (Fig.
7). BMPER contains five well conserved cysteine repeat regions
(CR1–5), which are involved in BMP binding. Interestingly,
these domains are absent in HJV, suggesting HJV must bind
BMPs by an alternative mechanism.
DISCUSSION
Anemia has been shown to strongly down-regulate liver hep-
cidin expression, even when iron stores are greatly increased as
found in Trfhpx/hpx mice (4, 21). This has led to the notion that
one or more secreted humoral factors are released from the
marrowunder increased erythropoietic drive that can influence
hepatic hepcidin levels. Levels of GDF15 and TWSG1 in the
marrow are increased in patients with -thalassemia, and both
have been shown to inhibit hepcidin production in vitro, the
FIGURE 2. Effect of soluble BMPER on hepcidin promoter activity and pSMAD levels in HepG2 and HuH7 cells. A, luciferase assays showing effect of BMPER
on BMP2-dependent activation on the WT hepcidin promoter and mutant (BMP-RE2) constructs in HepG2 cells. B, HuH7 cells treated as above. Lower panels,
Western blots showing pSMAD1/5/8 levels in the respective cells under the same conditions. Cells were exposed to 25 ng/ml BMP2 and 2500 ng/ml BMPER or
a combination of these. When given together, the molar ratio was 1:15 (BMP2:BMPER). C, densitometry from Western blots performed in triplicate showing the
ratio of pSMAD1/5/8:SMAD1 in HepG2 cells (*, p  0.05 BMP2 alone compared with BMP2BMPER, Student’s t test). D, diagrammatic representation of WT
hepcidin promoter luciferase construct used with three intact BMP response elements (BMP-RE1–3) and mutated construct in which BMP-RE2 was mutated.
Luciferase assays shown are means  S.D. derived from a single experiment with three biological replicates, and the experiment shown is representative of
three similar experiments (*, p  0.001 control versus BMP2; †, p  0.001 BMP2 versus BMPER and BMP2 versus BMPERBMP2, multiple ANOVA with Tukey’s post
hoc analysis). Densitometry was performed on Western blots using three biological replicates for each condition.
FIGURE 3. Effect of BMPER on hepcidin mRNA levels in primary human
hepatocytes. Effect of BMPER (2500 ng/ml) added to medium for 16 h on
hepcidin levels in primary hepatocytes in the presence and absence of BMP2
(25 ng/ml). Experiment shows mean  S.D. of three biological replicates for
each condition. *, p  0.05 control versus BMP2; †, p  0.01 BMP2 versus
BMPER; ††, p  0.01 BMP2 versus BMP2BMPER (one-way ANOVA with
Tukey’s post hoc analysis).
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latter by inhibiting the action of BMP4 and BMP2 (15). Bartni-
kas et al. found that bothGdf15 and Twsg1 levels were raised in
spleen of Trfhpx/hpx mice; however, when erythropoiesis was
FIGURE 4. Effect of BMPER and TWSG1 on BMP2- and BMP6-dependent
hepcidin promoter activity in HepG2 cells. A, luciferase reporter assays
showing the effect of increasing doses of BMPER (1–5000 ng/ml) on BMP6 (25
ng/ml)- and BMP2 (25 ng/ml)-dependent hepcidin promoter activity (*, p 
0.03; , p  0.01 compared with control levels, multiple ANOVA with Tukey’s
post hoc analysis). B, effect of BMPER (1–1000 ng/ml) and TWSG1 (1–1000
ng/ml) alone or in combination on BMP2 (25 ng/ml)-dependent hepcidin
promoter activity (*, p  0.05; , p  0.01; multiple ANOVA with Tukey’s post
hoc analysis). Luciferase assays shown are means  S.D. derived from a single
experiment with three biological replicates, and the experiment shown is
representative of three similar experiments.
FIGURE 5. Effect of BMPER peptide on serum iron and liver hepcidin in
CD1 mice. 7-week-old male mice received an intraperitoneal injection of
either 50 g of BMPER in PBS or PBS alone. Mice were sacrificed 18 h after
injection, and serum iron and liver hepcidin levels were measured (n  4 mice
per group; p values are shown from Student’s t test).
FIGURE 6. Expression levels of other potential hepcidin modifiers in liver
and muscle of Trfhpx/hpx versus control mice. A, qPCR showing relative
expression of BMP antagonists, Hjv, Noggin, Chordin, Twsg1, and hepcidin
modulator Gdf15 expression in liver of male Trfhpx/hpx mice versus age-
matched Trfhpx/ male mice (four mice per group). B, qPCR showing relative
expression of Hjv, Noggin, and Chordin mRNA levels in muscle in the same
mice as above.
FIGURE 7. Sequence comparison of BMPER, Cv-2, and Hjv. Upper panel,
BMPER, Hjv, and Cv-2 share a common von Willebrand type D domain (vWD),
a fully conserved acid-sensitive autocatalytic cleavage site, and a C-terminal
furin cleavage site. BMPER and Cv-2 contain five N-terminal cysteine-rich
regions (CR1–5), which are involved in binding BMPs; these domains are
absent in Hjv. Lower panel, multiple alignment (Clustal) of mouse, human, and
zebrafish BMPER and Hjv sequences showing a fully conserved acid-sensitive
autocatalytic cleavage site. TI  trypsin inhibitor domain.
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inhibited with doxorubicin, levels of both decreased without
significant change in liver hepcidin levels. This suggests Gdf15
and Twsg1may be markers for increased erythropoiesis but do
not directly regulate hepcidin in vivo (26).We found thatGdf15
levels were increased in liver of Trfhpx/hpx mice, which may be
reflective of some extra medullary or stress erythropoiesis
occurring in liver of Trfhpx/hpx mice. However, no changes in
Twsg1,Hjv, or other known BMP antagonistsNoggin andChor-
dinwere observed.We also found no changes inHjv,Noggin, or
Chordin in skeletal muscle of Trfhpx/hpx. Hence, of the BMP
antagonists tested, only Bmper was highly up-regulated in
Trfhpx/hpx mice.
Our results revealed that excess soluble BMPER peptide
inhibited BMP-dependent hepcidin transcription as well as
endogenous hepcidin production in hepatocytes by acting as an
anti-Bmp and inhibiting the SMAD pathway. The mechanism
is likely based on the ability of BMPER to bind and sequester
BMP molecules with high affinity and thereby prevent BMPs
from binding to BMP type I and II receptors (28, 29). It is note-
worthy that in some situations Bmper has been shown to elicit
pro-BMP responses, a function that may be dependent on
whether the protein is membrane-associated or soluble (28). In
this respect, BMPER may function in a similar manner to HJV
where the soluble form is anti-BMP and membrane form is
pro-BMP. Both HJV and BMPER share several structural fea-
tures such as a conserved autocatalytic cleavage site and C-ter-
minal furin cleavage sites. In our study we did not test the effect
of full-length membrane-associated BMPER; however, we did
not observe pro-BMP effects using the soluble BMPER peptide.
BMPER has been shown to bind to BMP2, -4, and -6 (17). In
agreement our results showed that BMPER inhibited the effects
of both BMP2 and BMP6 on hepcidin production, although the
effect on BMP6 was less pronounced than that for BMP2. The
reasons for this are not clear as yet; however, BMPER is likely to
bind to the various BMPs with different affinities.
TWSG1 has been shown to inhibit hepcidin (15) production
induced by BMP2 and -4 in hepatocytes, whereas other reports
suggest TWSG1 forms a ternary complex with Bmper and
Bmp4 (27) thereby increasing the binding of Bmp4 to Bmper. In
our experiment comparing relative effects of BMPER and
TWSG1 we used 25 ng of BMP2 and 1000 ng of TWSG1 and
BMPER. This is equivalent to a 1:23 molar ratio of BMP2 to
TWSG1 and a 1:6molar ratio of BMP2 to BMPER. Hence using
four times less BMPER than TWSG1 resulted in an 80% inhibi-
tion of BMP2-dependent activity, compared with 40%
for TWSG1. We therefore conclude that BMPER is more
potent than TWSG1 at inhibiting BMP-induced promoter
activity. This is consistent with data of others showing that the
zebrafish orthologue of BMPER, Cv-2, had a binding affinity for
BMP2 some 20-fold higher than TWSG1 and was considerably
more potent at inhibiting the binding of BMP2 to both BMP
type I and type II receptors (28). In summary we found that
BMPER was more potent at inhibiting BMP effects compared
with TWSG1, and there was no evidence of a significant
additive anti-BMP effect of BMPER and TWSG1 together.
Trfhpx/hpx mice have very low circulating levels of diferric
transferrin, and in common with human patients with -
thalassemia, very low hepatic hepcidin levels associated
with increased erythropoiesis. However, unlike -thalassemic
patients, Trfhpx/hpx mice do not have ineffective erythropoiesis.
Instead they have expanded marrow due to iron-restricted
erythropoiesis and exhibit life-long anemia and tissue hypoxia
due to the lack of transferrin. Reduced levels of Tfr2 have also
been reported in Trfhpx/hpx mouse liver, which may also con-
tribute to reduced hepcidin transcription (30). Although it is
not known whether one or a combination of these factors con-
FIGURE 8. Model showing mechanisms of hepcidin down-regulation in Trfhpx/hpx mice. Hepcidin levels in Trfhpx/hpx mice are suppressed by several
mechanisms: increased erythropoietic drive, decreased plasma Trf, decreased TfR2, and increased BMPER levels. The resulting increase in iron absorption leads
to liver iron loading, which increases liver BMP6 levels. Increased BMPER levels prevent positive regulation of hepcidin via BMP6.
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tributes to the lowered hepcidin in Trfhpx/hpx mice, evidence
suggests that both diferric transferrin levels and the anemia are
important (26, 31). Iron absorption is much higher and hepci-
din levels lower in Trfhpx/hpx mice compared with b-thalasse-
mic mice, and as a result iron accumulation in the liver is some
6-fold higher as well (32). This implies other factors are more
important than the anemia alone for hepcidin down-regulation
in Trfhpx/hpx mice. Bmp6 levels are increased in Trfhpx/hpx
mouse liver indicating that iron sensing is intact (26). Our find-
ing that the BMP ligand BMPER is significantly increased in
Trfhpx/hpx liver could explain why Trfhpx/hpx mice fail to elicit a
hepcidin response despite increased hepatic iron and BMP6
levels.
It has been suggested that BMPER plays a role in blood vessel
sprouting and remodeling, because mutations in the Bmper
gene (Cv-2) adversely affect the formation of small blood vessels
in Drosophila wing (16), whereas in zebrafish mutations affect
vasculogenesis and blood vessel remodeling (18). We hypothe-
size that, under severe chronic anemia as found in Trfhpx/hpx
mice, BMPER levels are raised to support blood vessel develop-
ment and remodeling, to counteract the anemia, leading to
increased levels of soluble BMPER, sequestration of BMPs, and
the down-regulation of hepatic hepcidin levels through inhibi-
tion of the SMAD signaling pathway (Fig. 8).
In summary, hepcidin down-regulation in Trfhpx/hpx mice is
likely to be a complex interplay of a number of factors exerting
downward repression on hepcidin. BMPER adds to the list of
factors that can suppress hepcidin levels and therefore affect
iron metabolism. Increased BMPER levels in Trfhpx/hpx mice
would also explain why increased BMP6 fails to induce an
increase in hepcidin levels. BMPERmay play a role in suppress-
ing hepcidin in other forms of severe chronic anemia with iron
loading or in diseases where there is a significant amount of
angiogenesis.
Acknowledgment—We acknowledge the help of Estibaliz Aldecoa-
Otalora Astarloa.
REFERENCES
1. Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., and
Loréal, O. (2001) A new mouse liver-specific gene, encoding a protein
homologous to human antimicrobial peptide hepcidin, is overexpressed
during iron overload. J. Biol. Chem. 276, 7811–7819
2. Park, C. H., Valore, E. V., Waring, A. J., and Ganz, T. (2001) Hepcidin, a
urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276,
7806–7810
3. Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B.,
Kahn, A., and Vaulont, S. (2001) Lack of hepcidin gene expression and
severe tissue iron overload in upstream stimulatory factor 2 (USF2)
knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98, 8780–8785
4. Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I.,
Beaumont, C., Kahn, A., and Vaulont, S. (2002) The gene encoding the
iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and
inflammation. J. Clin. Invest. 110, 1037–1044
5. Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., and
Ganz, T. (2003) Hepcidin, a putative mediator of anemia of inflammation,
is a type II acute-phase protein. Blood 101, 2461–2463
6. Nemeth, E., Tuttle,M. S., Powelson, J., Vaughn,M. B., Donovan, A.,Ward,
D. M., Ganz, T., and Kaplan, J. (2004) Hepcidin regulates cellular iron
efflux by binding to ferroportin and inducing its internalization. Science
306, 2090–2093
7. De Domenico, I., Ward, D. M., Langelier, C., Vaughn, M. B., Nemeth, E.,
Sundquist, W. I., Ganz, T., Musci, G., and Kaplan, J. (2007) Themolecular
mechanism of hepcidin-mediated ferroportin down-regulation.Mol. Biol.
Cell 18, 2569–2578
8. Nemeth, E., and Ganz, T. (2006) Regulation of iron metabolism by hepci-
din. Annu. Rev. Nutr. 26, 323–342
9. Nemeth, E., and Ganz, T. (2006) Hepcidin and iron-loading anemias.
Haematologica 91, 727–732
10. Babitt, J. L., Huang, F.W.,Wrighting, D.M., Xia, Y., Sidis, Y., Samad, T. A.,
Campagna, J. A., Chung, R. T., Schneyer, A. L., Woolf, C. J., Andrews,
N. C., and Lin, H. Y. (2006) Bone morphogenetic protein signaling by
hemojuvelin regulates hepcidin expression. Nat. Genet. 38, 531–539
11. Babitt, J. L., Huang, F. W., Xia, Y., Sidis, Y., Andrews, N. C., and Lin, H. Y.
(2007) Modulation of bone morphogenetic protein signaling in vivo reg-
ulates systemic iron balance. J. Clin. Invest. 117, 1933–1939
12. Andriopoulos, B., Jr., Corradini, E., Xia, Y., Faasse, S. A., Chen, S.,
Grgurevic, L., Knutson,M.D., Pietrangelo, A., Vukicevic, S., Lin,H. Y., and
Babitt, J. L. (2009) BMP6 is a key endogenous regulator of hepcidin expres-
sion and iron metabolism. Nat. Genet. 41, 482–487
13. Meynard, D., Kautz, L., Darnaud, V., Canonne-Hergaux, F., Coppin, H.,
and Roth, M. P. (2009) Lack of the bone morphogenetic protein BMP6
induces massive iron overload. Nat. Genet. 41, 478–481
14. Bier, E. (2008) Intriguing extracellular regulation of BMP signaling. Dev.
Cell 15, 176–177
15. Tanno, T., Porayette, P., Sripichai, O., Noh, S. J., Byrnes, C., Bhupatiraju, A.,
Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., Paulson, R. F., andMiller,
J. L. (2009) Identification of TWSG1 as a second novel erythroid regulator of
hepcidin expression in murine and human cells. Blood 114, 181–186
16. Conley, C. A., Silburn, R., Singer, M. A., Ralston, A., Rohwer-Nutter, D.,
Olson, D. J., Gelbart, W., and Blair, S. S. (2000) Crossveinless 2 contains
cysteine-rich domains and is required for high levels of BMP-like activity
during the formation of the cross veins in Drosophila. Development 127,
3947–3959
17. Moser, M., Binder, O., Wu, Y., Aitsebaomo, J., Ren, R., Bode, C., Bautch,
V. L., Conlon, F. L., and Patterson, C. (2003) BMPER, a novel endothelial
cell precursor-derived protein, antagonizes bone morphogenetic protein
signaling and endothelial cell differentiation. Mol. Cell. Biol. 23,
5664–5679
18. Moser,M., Yu, Q., Bode, C., Xiong, J.W., and Patterson, C. (2007) BMPER
is a conserved regulator of hematopoietic and vascular development in
zebrafish. J. Mol. Cell. Cardiol. 43, 243–253
19. Rentzsch, F., Zhang, J., Kramer, C., Sebald, W., and Hammerschmidt, M.
(2006) Crossveinless 2 is an essential positive feedback regulator of Bmp
signaling during zebrafish gastrulation. Development 133, 801–811
20. Binnerts, M. E.,Wen, X., Canté-Barrett, K., Bright, J., Chen, H. T., Asundi,
V., Sattari, P., Tang, T., Boyle, B., Funk, W., and Rupp, F. (2004) Human
Crossveinless-2 is a novel inhibitor of bone morphogenetic proteins.
Biochem. Biophys. Res. Commun. 315, 272–280
21. Weinstein, D. A., Roy, C. N., Fleming, M. D., Loda, M. F., Wolfsdorf, J. I.,
and Andrews, N. C. (2002) Inappropriate expression of hepcidin is asso-
ciated with iron refractory anemia. Implications for the anemia of chronic
disease. Blood 100, 3776–3781
22. McKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D.,
Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., Hediger, M. A., Hentze,
M. W., and Simpson, R. J. (2000) A novel duodenal iron-regulated trans-
porter, IREG1, implicated in the basolateral transfer of iron to the circu-
lation.Mol. Cell 5, 299–309
23. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(C(T)) Method.
Methods 25, 402–408
24. Casanovas,G.,Mleczko-Sanecka,K.,Altamura, S.,Hentze,M.W., andMuck-
enthaler, M. U. (2009) Bone morphogenetic protein (BMP)-responsive ele-
ments located in the proximal and distal hepcidin promoter are critical for its
response to HJV/BMP/SMAD. J. Mol. Med. 87, 471–480
25. Mitry, R. R., Hughes, R. D., Aw, M. M., Terry, C., Mieli-Vergani, G., Gir-
landa, R., Muiesan, P., Rela, M., Heaton, N. D., and Dhawan, A. (2003)
Human hepatocyte isolation and relationship of cell viability to early graft
BMPER Acts as a Negative Regulator of Hepcidin
FEBRUARY 3, 2012 • VOLUME 287 • NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 4105
function. Cell Transplant. 12, 69–74
26. Bartnikas, T. B., Andrews, N. C., and Fleming, M. D. (2011) Transferrin is
a major determinant of hepcidin expression in hypotransferrinemic mice.
Blood 117, 630–637
27. Ambrosio, A. L., Taelman, V. F., Lee, H. X., Metzinger, C. A., Coffinier, C.,
andDe Robertis, E.M. (2008) Crossveinless-2 Is a BMP feedback inhibitor
that binds Chordin/BMP to regulate Xenopus embryonic patterning.Dev.
Cell 15, 248–260
28. Zhang, J. L., Huang, Y., Qiu, L. Y., Nickel, J., and Sebald, W. (2007) von
Willebrand factor type C domain-containing proteins regulate bonemor-
phogenetic protein signaling through different recognition mechanisms.
J. Biol. Chem. 282, 20002–20014
29. Zhang, J. L., Qiu, L. Y., Kotzsch, A., Weidauer, S., Patterson, L., Hammer-
schmidt, M., Sebald, W., andMueller, T. D. (2008) Crystal structure anal-
ysis reveals how theChordin familymember crossveinless 2 blocks BMP-2
receptor binding. Dev. Cell 14, 739–750
30. Robb, A., and Wessling-Resnick, M. (2004) Regulation of transferrin re-
ceptor 2 protein levels by transferrin. Blood 104, 4294–4299
31. Raja, K. B., Pountney, D. J., Simpson, R. J., and Peters, T. J. (1999) Impor-
tance of anemia and transferrin levels in the regulation of intestinal iron
absorption in hypotransferrinemic mice. Blood 94, 3185–3192
32. Latunde-Dada, G. O., McKie, A. T., and Simpson, R. J. (2006) Animal
models with enhanced erythropoiesis and iron absorption. Biochim. Bio-
phys. Acta 1762, 414–423
BMPER Acts as a Negative Regulator of Hepcidin
4106 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 6 • FEBRUARY 3, 2012
